Has DSIP been tested in human clinical trials?

Yes, though the data is older and more limited than for many peptides, dating mostly to the late 1970s through early 1990s. Evidence is mixed: small human studies reported increased sleep pressure and improved sleep efficiency after DSIP administration, but a double-blind trial in chronic insomnia patients found limited therapeutic benefit from short-term treatment.

Does DSIP actually work as a sleep aid?

The evidence is mixed. Small human studies from the 1980s reported increased sleep pressure and improved sleep efficiency after DSIP administration, but a double-blind trial in chronic insomnia patients found limited therapeutic benefit from short-term treatment. Researchers who have reviewed the literature describe DSIP's overall effects as an unresolved question.

What dose was used in DSIP's original human trials versus research-community protocols?

Early controlled human trials used intravenous infusions such as 25 nmol/kg in a supervised clinical setting, timed to measure acute sleep pressure. Research-community protocols for subcutaneous use commonly cite roughly 100-300mcg once nightly, but that figure comes from community convention rather than a validated dosing trial, and the two are not directly comparable.

DSIP Human Studies: Old Data, Unresolved Results

Q: Is DSIP FDA-approved?

No. DSIP is not an FDA-approved drug. It is sold by suppliers as a research chemical for laboratory research use only, not for human consumption. It is not currently listed in the FDA's 503A bulk drug substances list, and in mid-2026 an FDA advisory committee issued an unfavorable recommendation regarding the related substance emideltide for compounding use.

Quick Evidence Summary

Evidence type	Current status
Human trials	Exist, but dated (late 1970s-early 1990s) and limited in scope
Early controlled IV studies	Reported acute sleep-pressure and sleep-efficiency effects
Double-blind insomnia trial	Found limited therapeutic benefit from short-term treatment
Literature reviewers' conclusion	DSIP's overall physiological role remains unresolved
Regulatory status	Not FDA-approved; sold as a research chemical

What DSIP Is

DSIP (Delta Sleep-Inducing Peptide) is studied for its proposed role in promoting slow-wave sleep and possibly normalizing cortisol levels. Unlike most compounds covered on this site, it has real human trial data, but that data is older and thinner than its name might suggest, and the results don't uniformly support its name's implication.

What the Human Trials Actually Found

Human data on DSIP is older and more limited than for many peptides in this category, dating mostly to the late 1970s through early 1990s. A controlled study of intravenous DSIP in healthy volunteers reported an immediate sense of sleep pressure and a measurable increase in subsequent sleep within the following hours, along with some delayed effects on the following night's sleep architecture.

However, a separate double-blind trial in patients with chronic insomnia found that short-term DSIP treatment was not likely to provide major therapeutic benefit. Reviewers of the broader literature have concluded that DSIP's overall physiological role remains unresolved rather than firmly established.

Why this matters: DSIP is unusual in this series for actually having decades-old controlled human data, which is more than exists for many research peptides. But having old human data isn't the same as having a clear, positive result: the honest summary is a mixed picture that researchers themselves describe as unresolved, not a validated sleep treatment.

Research reference: Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior." Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345. PMID: 6895513.

Evidence Gaps and Regulatory Status

DSIP is not an FDA-approved drug. It is sold by suppliers as a research chemical for laboratory research use only, not for human consumption. It is not currently listed in the FDA's 503A bulk drug substances list (21 CFR 216.23), and in mid-2026 an FDA advisory committee issued an unfavorable recommendation regarding the related substance emideltide for compounding use, a regulatory signal worth tracking for how it might affect DSIP's own standing. There's also a dosing gap worth flagging: early controlled human trials used precise IV infusions in a supervised clinical setting, while the subcutaneous nightly dosing convention seen in research-community protocols has not been validated in a controlled trial.

Bloodwork to Track

Given DSIP's proposed cortisol-normalizing mechanism, a morning cortisol level is a reasonable marker to track. See the peptide bloodwork guide for what a general baseline panel typically includes.

For dosing details and the full regulatory breakdown, see the DSIP reference page. For a broader look at how sleep-support compounds fit into a research protocol, see the peptide stack beginner's guide. BioStackIQ's Rate My Stack can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.

Frequently Asked Questions

Disclaimer: This content is for informational purposes only. DSIP is a research compound not approved by the FDA for human use, and the human evidence base is limited and dated. Always consult a qualified healthcare provider before starting any research compound protocol. Nothing in this article constitutes medical advice.